Skip to main content

A Descriptive Analysis of Weight Loss Medication Use, Including GLP-1 RA Products, and Intentional Self-Harm among Patients with Obesity in FDA's Sentinel Distributed Database

Basic Details
Date
Type
Presentation
Description

This poster describes a project in which FDA assessed use of weight loss medications, including GLP-1RAs, and evaluated the occurrence of intentional self-harm among a large cohort of health plan members with obesity and without diabetes in the United States. It was presented at the 2026 ISPE Annual Meeting. 

Materials

A Descriptive Analysis of Weight Loss Medication Use, Including GLP-1 RA Products, and Intentional Self-Harm among Patients with Obesity in FDA's Sentinel Distributed Database

Information
Host

International Society for Pharmacoepidemiology

Related Assessment(s)
Sentinel Drug Study: Glucagon-Like Peptide-1 Receptor Agonists & Intentional Self-Harm
Sentinel Drug Analysis: Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Obesity: A Descriptive Analysis
2026 ISPE Annual Meeting
Presenter(s)

Jennifer G. Lyons

Author(s)

Jennifer G. Lyons, Van Tran, Jamal T. Jones, Sarah K. Dutcher, Meg Her, Maria E. Kempner, Joo-Yeon Lee, Andrew Mosholder, Katherine E. Round, Sengwee Toh, Aida Kuzucan